Literature DB >> 15359243

Topically applied antibody fragments penetrate into the back of the rabbit eye.

K A Williams1, H M Brereton, A Farrall, S D Standfield, S D Taylor, L A Kirk, D J Coster.   

Abstract

AIMS: Antibody fragments have been shown to penetrate into the anterior chamber when applied to the cornea. The aim of this study was to investigate whether such fragments could penetrate into the vitreous cavity after topical administration to the ocular surface of rabbits.
METHODS: An engineered single-chain variable-domain antibody fragment with specificity for an irrelevant rat determinant was applied as a 50 microl eye drop to the eyes of live rabbits at 20-min intervals over 12 h. Eye drops contained 0.8-1.1 mg/ml protein in a buffered salt solution supplemented with penetration and viscosity enhancers. Samples were collected by paracentesis from the vitreous cavity immediately postmortem. Antibody fragments in these samples were quantified by measuring the binding activity to specific antigen, using flow cytometry.
RESULTS: Topically applied antibody fragments were detectable in the vitreous of rabbit eyes after 4-12 h but had cleared at 12 h following the final eye drop. Concentrations of the antibody fragment in the vitreous samples were estimated to be 50-150 ng/ml at 12 h. Penetration of the parental whole antibody into the vitreous was not observed.
CONCLUSION: Antibody fragments penetrate into the vitreous chamber of the rabbit eye after topical administration to the ocular surface. Such fragments may have therapeutic potential for diseases affecting the posterior segment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15359243     DOI: 10.1038/sj.eye.6701669

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  8 in total

1.  Corneal penetration of topical and subconjunctival bevacizumab.

Authors:  Mohammad H Dastjerdi; Zahra Sadrai; Daniel R Saban; Qiang Zhang; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

2.  Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application.

Authors:  Marianne Berdugo; Inna V Larsen; Claire Abadie; Catherine Deloche; Laura Kowalczuk; Elodie Touchard; Richard Dubielzig; Curtis R Brandt; Francine Behar-Cohen; Jean-Marc Combette
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

Review 3.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

Authors:  Abhirup Mandal; Dhananjay Pal; Vibhuti Agrahari; Hoang My Trinh; Mary Joseph; Ashim K Mitra
Journal:  Adv Drug Deliv Rev       Date:  2018-01-13       Impact factor: 15.470

4.  Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye.

Authors:  J J Chen; S E Ebmeier; W M Sutherland; N G Ghazi
Journal:  Eye (Lond)       Date:  2011-09-16       Impact factor: 3.775

5.  Delivery of Topically Applied Calpain Inhibitory Peptide to the Posterior Segment of the Rat Eye.

Authors:  Taku Ozaki; Mitsuru Nakazawa; Tetsuro Yamashita; Sei-Ichi Ishiguro
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

6.  Eye drop delivery of pigment epithelium-derived factor-34 promotes retinal ganglion cell neuroprotection and axon regeneration.

Authors:  Vasanthy Vigneswara; Maryam Esmaeili; Louise Deer; Martin Berry; Ann Logan; Zubair Ahmed
Journal:  Mol Cell Neurosci       Date:  2015-08-08       Impact factor: 4.314

Review 7.  Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation.

Authors:  Gerard A Rodrigues; David Lutz; Jie Shen; Xiaoda Yuan; Hong Shen; James Cunningham; Hongwen M Rivers
Journal:  Pharm Res       Date:  2018-10-29       Impact factor: 4.200

Review 8.  Topical Drug Delivery to the Posterior Segment of the Eye.

Authors:  Marina Löscher; Chiara Seiz; José Hurst; Sven Schnichels
Journal:  Pharmaceutics       Date:  2022-01-06       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.